Laurus Labs

Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad, Telangana. Founded in 2005 by Satyanarayana Chava, the company develops and manufactures active pharmaceutical ingredients (APIs), pharmaceutical intermediates, generic finished-dose formulations, contract development and manufacturing services, biotechnology products, veterinary APIs, and specialty chemicals. The company is particularly associated with large-scale API manufacturing for antiretroviral medicines. Its portfolio also extends into oncology, cardiovascular medicine, antidiabetic products, antiviral medicines, and other therapeutic areas. Laurus Labs has described itself as a major third-party supplier of antiretroviral APIs and supplies APIs to many leading generic-drug companies. Its manufacturing and development model combines process research, analytical capabilities, regulated production, and formulation activities intended for international pharmaceutical customers. Laurus Labs operates manufacturing facilities in Visakhapatnam, Hyderabad, and Bengaluru. According to the company information summarized in the Wikipedia reference, its eight manufacturing plants have received one or more regulatory approvals from authorities and agencies including the United States Food and Drug Administration, the World Health Organization, NIP Hungary, the Korean Ministry of Food and Drug Safety, the United Kingdom Medicines and Healthcare products Regulatory Agency, Australia's Therapeutic Goods Administration, and Japan's Pharmaceuticals and Medical Devices Agency. These approvals support the company's ability to supply products for regulated markets, although approval status can vary by facility and product. The business is organized around four broad areas: generic formulations, generic APIs, contract development and manufacturing through Laurus Synthesis, and biotechnology and specialty chemicals. Laurus Synthesis serves customers in the United States, European Union, and Japan, while the company's research network includes centers in Hyderabad, Visakhapatnam, and the United States. Its research activities cover contract research, clinical research, analytical research, process development, and manufacturing scale-up. Laurus Labs expanded into biotechnology in 2020 through the acquisition of Richcore Lifesciences. Richcore was subsequently renamed Laurus Bio and became a subsidiary of Laurus Labs. Laurus Bio focuses on biotechnology manufacturing and fermentation-based products; the referenced material states that it had commissioned 180 kilolitres of fermentation capacity for food proteins by 2022. The company also received United States regulatory approval in March 2020 to market hydroxychloroquine tablets and announced that it would supply the medicine for clinical trials investigating preventive treatment for COVID-19. This episode illustrated Laurus Labs' presence in generic pharmaceutical manufacturing, while also placing one of its products within the wider public-health and clinical-research debate of the early COVID-19 period. Laurus Labs' positioning is based on a combination of cost-efficient manufacturing, pharmaceutical quality systems, research and development, and access to regulated global markets. Its scope has broadened from API manufacturing into finished formulations, CDMO services, biotechnology, and specialty products, while its publicly available reference profile does not establish a single consumer-facing product brand as the company's defining identity.

Laurus Labs was established in India in 2005 by Satyanarayana Chava. From its origins, the company developed around pharmaceutical research, process development, and manufacturing, with a particular emphasis on active pharmaceutical ingredients and intermediates. Its growth model was aimed at supplying pharmaceutical companies rather than building a predominantly consumer-facing medicines brand. The company developed capabilities across several therapeutic and technical areas. Antiretroviral APIs became an important part of its identity, alongside products for oncology, cardiovascular treatment, antiviral therapy, diabetes care, and other pharmaceutical applications. Laurus Labs has stated that it supplies APIs to nine of the ten largest generic pharmaceutical companies in the world and has characterized itself as the world's largest third-party supplier of APIs for antiretroviral medicines. These descriptions place the company within the global supply chain for generic and essential medicines. Laurus Labs expanded its manufacturing footprint across Visakhapatnam, Hyderabad, and Bengaluru. The referenced profile describes eight manufacturing plants, with facilities receiving approvals or clearances from international regulatory bodies including the USFDA, WHO, NIP Hungary, South Korea's KFDA, the UK's MHRA, Australia's TGA, and Japan's PMDA. The company also established research and development centers in Hyderabad, Visakhapatnam, and the United States. These sites support activities described as contract research, clinical research, analytical research, process development, and manufacturing support. The business gradually broadened beyond APIs. Its generic formulation division produces finished-dose medicines, while Laurus Synthesis provides custom synthesis and contract development and manufacturing services. The United States, European Union, and Japan are identified as important markets for this CDMO activity. The company also operates in biotechnology, veterinary APIs, agrochemicals, and specialty chemicals, giving it a portfolio that extends beyond conventional generic API production. A major diversification step occurred in 2020, when Laurus Labs acquired Richcore Lifesciences, an Indian biotechnology company. Following the transaction, Richcore was renamed Laurus Bio and became a subsidiary. This move gave Laurus Labs a dedicated biotechnology platform and expanded its capabilities into fermentation and biological manufacturing. By 2022, Laurus Bio had placed 180 kilolitres of fermentation capacity for food proteins into operation, according to the supplied reference material. The year 2020 also brought Laurus Labs into the public discussion surrounding COVID-19 treatments. In March, the company received USFDA approval to market hydroxychloroquine tablets and said it would supply the product for clinical trials investigating preventive treatment. The approval concerned a generic pharmaceutical product and did not itself establish clinical efficacy for COVID-19 prevention. Laurus Labs' history therefore reflects a progression from API and intermediate manufacturing toward a diversified pharmaceutical and biotechnology platform. Its current profile combines generic formulations, regulated API production, CDMO and custom synthesis, biotechnology, fermentation, veterinary products, and specialty chemicals. The supplied sources do not provide enough information to document every subsequent corporate, financial, or leadership development, so those areas remain limited here.

• 2022

  Laurus Bio fermentation capacity operational

  [1]Laurus Labsen.wikipedia.org

  Laurus Bio had placed 180 kilolitres of fermentation capacity for food proteins into operation.

• 2021

  Laurus Ingredients incorporated

  [2]Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%indiainfoline.com

  A Laurus Labs subsidiary incorporated Laurus Ingredients as part of the group's diversification.

• 2020

  Entry into biotechnology through Richcore acquisition

  [1]Laurus Labsen.wikipedia.org

  Laurus Labs acquired Richcore Lifesciences and subsequently renamed the business Laurus Bio.

• 2020

  USFDA approval for hydroxychloroquine tablets

  [1]Laurus Labsen.wikipedia.org

  The company received USFDA approval to market hydroxychloroquine tablets and announced supply for COVID-19 preventive-treatment clinical trials.

• 2005

  Laurus Labs founded

  [1]Laurus Labsen.wikipedia.org

  Satyanarayana Chava founded Laurus Labs in India, establishing the company that would develop into a pharmaceutical and biotechnology manufacturer.

A research-led, cost-efficient pharmaceutical manufacturing and biotechnology company serving regulated international markets through APIs, generic formulations, CDMO services, and fermentation-based products.

• Active pharmaceutical ingredients

  Generic APIs

  Laurus Labs manufactures APIs used in generic medicines across areas including antiretroviral therapy, oncology, cardiovascular treatment, antiviral therapy, and diabetes care. API production is central to the company's manufacturing model and connects it to large international generic-drug companies.

• HIV/AIDS medicines

  Antiretroviral APIs

  The company is especially associated with antiretroviral APIs and has described itself as a major third-party supplier in this field. Its referenced portfolio includes products related to dolutegravir, lamivudine, and tenofovir combination therapy.

• Generic pharmaceuticals

  Generic finished-dose formulations

  The finished-dose formulation division converts pharmaceutical ingredients into marketable dosage forms. The portfolio includes products in several therapeutic categories, including antiretroviral and other widely used generic medicines.

• Generic pharmaceutical tablets · 2020

  Hydroxychloroquine tablets

  Laurus Labs received USFDA approval in March 2020 to market hydroxychloroquine tablets. The company also announced that it would supply the product for clinical trials concerning possible COVID-19 preventive treatment.

• Contract development and manufacturing

  Laurus Synthesis

  Laurus Synthesis is the group's CDMO subsidiary and provides custom synthesis, development, and manufacturing capabilities. Its principal international markets are identified as the United States, European Union, and Japan.

• Biotechnology and fermentation · 2020

  Laurus Bio

  Laurus Bio is the biotechnology subsidiary created after the acquisition and renaming of Richcore Lifesciences. Its activities include biotechnology manufacturing and fermentation, including capacity for food proteins.

• 2021

  Merck files Januvia patent suit against Laurus

  Merck Sharp & Dohme Corp. filed a patent suit in the District of Delaware against Laurus Labs Limited and Laurus Generics Inc. after the defendants submitted an ANDA to the FDA seeking to produce a generic version of Januvia. Merck is seeking a declaration of patent infringement; the filing describes the alleged infringement, not a court determination.

  Source

Read more

• 2021

  Incorporation of Laurus IngredientsStrategy

  Background

  The Laurus group continued diversifying its business structure beyond its core API operations.

  Action taken

  A Laurus Labs subsidiary incorporated Laurus Ingredients.

  Source

• 2020

  Acquisition of Richcore LifesciencesM&A

  Background

  Laurus Labs sought to expand beyond conventional pharmaceutical manufacturing and enter biotechnology.

  Action taken

  The company acquired Richcore Lifesciences, renamed it Laurus Bio, and made it a subsidiary.

  Aftermath

  The transaction created a dedicated biotechnology platform and was followed by development of fermentation capacity for food proteins.

  Source

• 2020

  USFDA-approved hydroxychloroquine tablet launchProduct launch

  Background

  During the early COVID-19 period, hydroxychloroquine was being investigated in clinical studies concerning possible treatment or prevention.

  Action taken

  Laurus Labs received USFDA approval to market hydroxychloroquine tablets and announced supply for preventive-treatment clinical trials.

  Aftermath

  The product became part of the company's COVID-19-era generic pharmaceutical activity; the supplied sources do not establish clinical outcomes or commercial results.

  Source

• 2021-08-12

  Merck files Januvia patent suit against Laurus[5]Merck files Januvia patent suit against Lauruslawstreetmedia.com

  Reported: 2021-08-13

  Merck Sharp & Dohme Corp. filed a patent suit in the District of Delaware against Laurus Labs Limited and Laurus Generics Inc. after the defendants submitted an ANDA to the FDA seeking to produce a generic version of Januvia. Merck is seeking a declaration of patent infringement; the filing describes the alleged infringement, not a court determination.

• 2021-01-20

  Laurus Labs completes acquisition of 72.55% of Richcore[6]Laurus Labs完成对Richcore 72.55%股权的收购equitybulls.com

  Reported: 2021-01-20

  Laurus Labs completed its acquisition of a 72.55% stake in Richcore Lifesciences Private Limited. Richcore became a subsidiary of Laurus Labs effective that day.

1. 1Laurus Labsen.wikipedia.org
2. 2Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%indiainfoline.com
3. 3Laurus Labs: Diversification to speed up in FY23; add on declinesmoneycontrol.com
4. 4Laurus Labs is already halfway past its $1 billion revenue target and has new capacities and products to back up its growth planmoneycontrol.com
5. 5Merck files Januvia patent suit against Lauruslawstreetmedia.com
6. 6Laurus Labs完成对Richcore 72.55%股权的收购equitybulls.com